Rita Murri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2140187/publications.pdf

Version: 2024-02-01

101543 110387 4,547 112 36 64 h-index citations g-index papers 113 113 113 4750 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 445-449.	2.1	405
2	Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S123-S127.	2.1	390
3	Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S136-S139.	2.1	238
4	Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. Psychosomatics, 2004, 45, 394-402.	2.5	231
5	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). Aids, 2002, 16, 369-379.	2.2	189
6	Attitudes towards Anti-SARS-CoV2 Vaccination among Healthcare Workers: Results from a National Survey in Italy. Viruses, 2021, 13, 371.	3.3	132
7	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 123-128.	2.1	120
8	The Effect of Potent Antiretroviral Therapy and JC Virus Load in Cerebrospinal Fluid on Clinical Outcome of Patients with AIDSâ€Associated Progressive Multifocal Leukoencephalopathy. Journal of Infectious Diseases, 2000, 182, 1077-1083.	4.0	113
9	Neurocognitive Performance and Quality of Life in Patients with HIV Infection. AIDS Research and Human Retroviruses, 2003, 19, 643-652.	1.1	107
10	Determinants of health-related quality of life in HIV-infected patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2003, 15, 581-590.	1,2	104
11	Variable Prediction of Antiretroviral Treatment Outcome by Different Systems for Interpreting Genotypic Human Immunodeficiency Virus Type 1 Drug Resistance. Journal of Infectious Diseases, 2003, 187, 1934-1943.	4.0	96
12	Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. International Journal of STD and AIDS, 2004, 15, 254-259.	1.1	84
13	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. Annals of Internal Medicine, 2019, 171, 695.	3.9	81
14	PCR detection of Toxoplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. Journal of Medical Microbiology, 1996, 45, 472-476.	1.8	72
15	Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. Aids, 2000, 14, F117-F121.	2.2	72
16	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. Journal of NeuroVirology, 2001, 7, 323-328.	2.1	68
17	Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. Aids, 2001, 15, 1579-1581.	2.2	67
18	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 123-128.	2.1	65

#	Article	IF	CITATIONS
19	Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review. Viruses, 2021, 13, 2110.	3.3	65
20	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. Journal of NeuroVirology, 2001, 7, 364-368.	2.1	64
21	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 184-190.	2.1	64
22	Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Aids, 1995, 9, 1343-1350.	2.2	62
23	Patient-reported and physician-estimated adherence to HAART. Journal of General Internal Medicine, 2004, 19, 1104-1110.	2.6	60
24	Incidence of Malignancies in HIVâ€Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study. Clinical Infectious Diseases, 2010, 50, 1316-1321.	5.8	56
25	Clinical and Virological Monitoring During Treatment with Intrathecal Cytarabine in Patients with AIDSâ€Associated Progressive Multifocal Leukoencephalopathy. Clinical Infectious Diseases, 1999, 28, 624-628.	5.8	55
26	Physician Estimates of Adherence and the Patient-Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S158-S162.	2.1	55
27	Sexual Dysfunction in HIV-Infected Men: Role of Antiretroviral Therapy, Hypogonadism and Lipodystrophy. Antiviral Therapy, 2007, 12, 1059-1066.	1.0	54
28	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. Antiviral Therapy, 2013, 18, 153-160.	1.0	52
29	Changing Disease Patterns in Focal Brain Lesion-Causing Disorders in AIDS. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 365-371.	0.3	46
30	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 407-416.	2.1	46
31	Quality of Life and Body Image in the Assessment of Psychological Impact of Lipodystrophy: Validation of the Italian Version of Assessment of Body Change and Distress Questionnaire. Quality of Life Research, 2006, 15, 173-178.	3.1	46
32	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) Tj ETQq0 0 0 rgBT /	Overlock 1	0 T∱\$0 212 T
33	Disease-Related Factors Associated With Health-Related Quality of Life in People With Nonadvanced HIV Disease Assessed Using an Italian Version of the MOS-HIV Health Survey. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 350-356.	0.3	45
34	Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 23-30.	2.1	44
35	Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. Aids, 2000, 14, 1660-1662.	2.2	42
36	Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of Life. AIDS Patient Care and STDs, 2008, 22, 577-585.	2.5	41

#	Article	IF	CITATIONS
37	Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. HIV Clinical Trials, 2003, 4, 99-106.	2.0	38
38	Cognitive Impairment in Asymptomatic Stages of HIV Infection. European Neurology, 1996, 36, 125-133.	1.4	35
39	Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals. AIDS Patient Care and STDs, 2008, 22, 291-299.	2.5	33
40	Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. Antiviral Therapy, 2004, 9, 291-296.	1.0	32
41	Self-Reported Nonadherence with Antiretroviral Drugs Predicts Persistent Condition. HIV Clinical Trials, 2001, 2, 323-329.	2.0	31
42	ISSQoL: A New Questionnaire for Evaluating the Quality of Life of People Living with HIV in the HAART Era*. Quality of Life Research, 2006, 15, 377-390.	3.1	27
43	Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. Aids, 2010, 24, 2408-2412.	2.2	27
44	Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 461.	2.1	24
45	Physicians' knowledge of health-related quality of life and perception of its importance in daily clinical practice. Health and Quality of Life Outcomes, 2010, 8, 43.	2.4	24
46	Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 461.	2.1	23
47	Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Annals of Hematology, 2007, 86, 225-226.	1.8	23
48	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scandinavian Journal of Infectious Diseases, 2014, 46, 34-45.	1.5	23
49	Initial antifungal strategy does not correlate with mortality in patients with candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 187-193.	2.9	22
50	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	3.0	22
51	Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. International Journal of Cardiology, 2020, 301, 190-194.	1.7	22
52	Trimethoprim–sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series. Infection, 2017, 45, 209-213.	4.7	21
53	Comparative performance evaluation of Wako \hat{l}^2 -glucan test and Fungitell assay for the diagnosis of invasive fungal diseases. PLoS ONE, 2020, 15, e0236095.	2.5	20
54	Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention. Antimicrobial Resistance and Infection Control, 2020, 9, 164.	4.1	20

#	Article	IF	CITATIONS
55	Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy. Antibiotics, 2022, 11, 3.	3.7	20
56	Sexual dysfunction in HIV infection. Lancet, The, 2007, 369, 905-906.	13.7	19
57	Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis. International Journal for Quality in Health Care, 2016, 28, 502-507.	1.8	19
58	Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia. Lancet, The, 1992, 340, 788.	13.7	18
59	Karnofsky Performance Status and Assessment of Global Health Status. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 294.	0.3	18
60	Prognostic factors of early fatal outcome and long-term survival in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. European Journal of Epidemiology, 1993, 9, 183-189.	5.7	16
61	Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. Journal of Medical Microbiology, 1996, 45, 146-148.	1.8	16
62	Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients. Lancet, The, 1999, 353, 1974.	13.7	16
63	Social media as a tool for scientific updating at the time of COVID pandemic: Results from a national survey in Italy. PLoS ONE, 2020, 15, e0238414.	2.5	16
64	Primary central nervous system lymphoma and brain biopsy in AIDS. Lancet, The, 1993, 341, 1411-1412.	13.7	15
65	Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. Clinical Microbiology and Infection, 2019, 25, 474-480.	6.0	15
66	A proposal for a comprehensive approach to infections across the surgical pathway. World Journal of Emergency Surgery, 2020, 15, 13.	5.0	15
67	Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. Expert Opinion on Pharmacotherapy, 2020, 21, 637-644.	1.8	15
68	Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antiviral Therapy, 2007, 12, 1059-65.	1.0	15
69	Fluconazole for Primary Prophylaxis of AIDS-associated Cryptococcosis: A Case-control Study. Scandinavian Journal of Infectious Diseases, 1995, 27, 235-237.	1.5	14
70	Presumptive Clinical Criteria Versus Endoscopy in the Diagnosis of Candida Esophagitis at Various HIV-1 Disease Stages. Endoscopy, 1995, 27, 371-376.	1.8	14
71	Systematic clinical management of patients with candidemia improves survival. Journal of Infection, 2018, 77, 145-150.	3.3	13
72	Circulating Levels andex VivoProduction of \hat{i}^2 -Chemokines, Interferon \hat{i}^3 , and Interleukin 2 in Advanced Human Immunodeficiency Virus Type 1 Infection: The Effect of Protease Inhibitor Therapy. AIDS Research and Human Retroviruses, 2000, 16, 835-843.	1.1	12

#	Article	IF	CITATIONS
73	Asymmetry of the Regimen Is Correlated to Self-Reported Suboptimal Adherence: Results From AdUCSC, a Cohort Study on Adherence in Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 411-412.	2.1	11
74	A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 167-173.	2.9	11
75	Performance evaluation of the (1,3)-& amp; beta; -D-glucan detection assay in non-intensive care unit adult patients. Infection and Drug Resistance, 2019, Volume 12, 19-24.	2.7	11
76	Oirect use of eazyplex [®] SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in Escherichia coli and Klebsiella pneumoniae bloodstream infections. Infection and Drug Resistance, 2019, Volume 12, 1055-1062.	2.7	11
77	Reduced utility of early procalcitonin and blood culture determination in patients with febrile urinary tract infections in the emergency department. Internal and Emergency Medicine, 2020, 15, 119-125.	2.0	11
78	Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. Aids, 2000, 14, 1655-1656.	2.2	11
79	Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients. Journal of Cancer Research and Clinical Oncology, 1992, 118, 635-636.	2.5	10
80	Rate and Predictors of Self-Chosen Drug Discontinuations in Highly Active Antiretroviral Therapy-Treated HIV-Positive Individuals. AIDS Patient Care and STDs, 2009, 23, 35-39.	2.5	8
81	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. Future Microbiology, 2015, 10, 15-20.	2.0	8
82	Comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: A cross-sectional survey. International Journal of Antimicrobial Agents, 2019, 54, 338-345.	2.5	8
83	Is "Once-Daily" Regimen a Key Strategy for Improving Adherence to Antiretroviral Regimens?. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 259-260.	2.1	7
84	Liver Resection for Primary Intrahepatic Stones: Focus on Postoperative Infectious Complications. World Journal of Surgery, 2016, 40, 433-439.	1.6	7
85	Host and disease factors are associated with cognitive function in European <scp>HIV</scp> â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	2,2	7
86	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEATOO1/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	3.0	7
87	Management of Recurrent Cutaneous Abscesses During Therapy With Infliximab. Clinical Therapeutics, 2011, 33, 1993-1996.	2.5	6
88	Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. AIDS Research and Therapy, 2016, 13, 18.	1.7	6
89	Early procalcitonin determination in the emergency department and clinical outcome of community-acquired pneumonia in old and oldest old patients. European Journal of Internal Medicine, 2020, 79, 51-57.	2,2	6
90	The Role of Early Procalcitonin Determination in the Emergency Departiment in Adults Hospitalized with Fever. Medicina (Lithuania), 2021, 57, 179.	2.0	6

#	Article	IF	CITATIONS
91	Prognostic Role of Serum Procalcitonin Measurement in Adult Patients Admitted to the Emergency Department with Fever. Antibiotics, 2021, 10, 788.	3.7	6
92	Nonnucleoside Reverse Transcriptase Inhibitor-Containing Regimens Are Associated With Increased Satisfaction With Sexual Life. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 532-534.	2.1	5
93	Access to gynecological services and Papanicolau tests in HIV-infected Italian women: A questionnaire survey. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2006, 18, 376-378.	1.2	5
94	Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. Infection, 2009, 37, 168-178.	4.7	5
95	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. Infectious Diseases, 2016, 48, 48-55.	2.8	5
96	IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clinical Infectious Diseases, 2018, 66, 1815-1816.	5.8	5
97	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 49-55.	2.1	4
98	Nursing home residence is associated with spread of Clostridium difficile ribotype 027 in central Italy. Journal of Hospital Infection, 2016, 94, 201-203.	2.9	4
99	Post-Prescription Audit Plus Beta-D-Glucan Assessment Decrease Echinocandin Use in People with Suspected Invasive Candidiasis. Medicina (Lithuania), 2021, 57, 656.	2.0	4
100	Declining Tuberculosis and Drug Resistance Rate Among HIV-Positive Patients at an Italian Teaching Hospital in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 546-547.	2.1	3
101	Highly active antiretroviral therapy. BMJ: British Medical Journal, 2005, 330, 681-682.	2.3	3
102	Antibiotic stewardship from toolkit to local implementation: the †gutta cavat lapidem' strategy. Future Microbiology, 2017, 12, 935-938.	2.0	3
103	Adherence to Protease Inhibitors. Annals of Internal Medicine, 2001, 134, 625.	3.9	2
104	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 49-55.	2.1	2
105	The Challenge of Identifying Resistant-Organism Pneumonia in the Emergency Department: Still Navigating on the Erie Canal?. Clinical Infectious Diseases, 2012, 54, 199-201.	5.8	2
106	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. Journal of Chemotherapy, 2021, 33, 435-439.	1.5	2
107	Machine Learning and Antibiotic Management. Antibiotics, 2022, 11, 304.	3.7	2
108	Management of mycotic aorto-iliac aneurysms: a 30-year monocentric experience. European Review for Medical and Pharmacological Sciences, 2020, 24, 3274-3281.	0.7	2

#	Article	lF	CITATIONS
109	Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis. Aids, 1996, 10, 1046-1047.	2.2	1
110	The role of procalcitonin outside of the Intensive Care Unit (ICU): a multidisciplinary approach. European Review for Medical and Pharmacological Sciences, 2019, 23, 2978-2985.	0.7	1
111	Partnership of HIV-Infected Women and Health Status. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 502-503.	2.1	0
112	Use of procalcitonin as a tool for antibiotic stewardship. Future Microbiology, 2019, 14, 77-79.	2.0	0